Answers are grounded in this paper and cite their sources.
Anaphylaxis is a severe, rapidly developing, and life-threatening systemic hypersensitivity reaction.The diagnosis of anaphylaxis is primarily clinical.Numerous studies on the mechanisms and the biomarkers of the disease are initiated every year.The biomarkers of anaphylaxis may become an important tool for the diagnosis, prevention, repeated risk assessment, severity stratification, and new therapeutic strategies for treatment of the disease.Various immune and non-immune mediators produced and released by effector cell populations are currently considered as biomarkers of anaphylaxis.Here, we review the current data on potential biomarkers of anaphylaxis and the possibilities and perspectives for their use in future clinical practice. Impact-statementSpecific, nonspecific and genetic biomarkers of anaphylaxis have been characterized.In addition to tryptase and sIgE, promising and practically applicable new biomarkers of AF are chymase, carboxypeptidase A3, CCL2 and basogranulin.Genetic biomarkers can predict AF severity and identify high-risk patients.
No takes yet. Share an insight, caveat, or question.
Пампура et al. (2024) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: